Coherus Shakes Up Ranibizumab Competition With First Interchangeable US Biosimilar
Cimerli Version Approved By FDA For All Five Indications Of Lucentis Reference Product
• By David Wallace
Coherus has the first US interchangeable Lucentis biosimilar • Source: Shutterstock 
